Swan Capital’s Gilead Sciences GILD Stock Holding History

Swan Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6	Closed	-$554	–	400
2024 Q4	$554	Buy	+6	New	+$540	﹤0.01%	315

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Swan Capital's GILD Position: Q1 2025 in Review

Swan Capital sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 6 shares — an estimated $554 sold.

Swan Capital first reported a position in GILD in Q4 2024 and held it in 1 quarter. The position peaked at $554 in Q4 2024. 2,013 funds tracked by Wall St. Rank hold GILD as of Q1 2025.

Swan Capital reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
Swan Capital sold 6 Gilead Sciences shares in Q1 2025, an estimated $554.
Swan Capital first reported a position in Gilead Sciences in Q4 2024 and held it in 1 quarter.
Swan Capital's Gilead Sciences position peaked at $554 in Q4 2024.
2,013 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.

Based on Swan Capital's 13F filing for Q1 2025, filed 23 May 2025.